Primary content

Related to 'CINSW author'

The target participation rate for BreastScreen has not yet been reached by any Australian jurisdiction. Qualitative research of barriers to screening may provide insight into how the participation rate may be increased.

Introduction of temozolomide into standard care in 2005 coincided with improvements in survival and a rapid increase in temozolomide prescribing.

RD-staging provided the greatest stage data completeness and alignment to AJCC-TNM for prostate cancers, followed by breast, then melanoma and lung cancers.

There was an increase in the incidence of colorectal cancer for people younger than 50 years for some jurisdictions, including Australia, which may be relating to changing prevalence of colorectal cancer risk factors (e.g. excess bodyweight) in younger populations.

People with cancer experience a higher use of primary and secondary healthcare services in the year preceding and following diagnosis, with GPs continuing to play a significant role post diagnosis.

The estimated risk of progression of lentigo maligna to lentigo maligna melanoma was 3.5% per year, with an average time for lentigo maligna to progress to lentigo maligna melanoma of 28.3 years.

177 Lu-DOTATATE is a promising treatment for advanced neuroendocrine tumours. Superior survival in patients who met selection criteria emphasise the importance of protocol adherence.

Emergency hospitalisations following chemotherapy for early breast cancer were relatively common, especially following docetaxel-containing protocols.